Sensors,
Год журнала:
2024,
Номер
24(9), С. 2904 - 2904
Опубликована: Май 1, 2024
Demand
is
strong
for
sensitive,
reliable,
and
cost-effective
diagnostic
tools
cancer
detection.
Accordingly,
bead-based
biosensors
have
emerged
in
recent
years
as
promising
platforms
based
on
wide-ranging
biomarkers
owing
to
the
versatility,
high
sensitivity,
flexibility
perform
multiplexing
of
beads.
This
comprehensive
review
highlights
trends
innovations
development
cancer-biomarker
We
introduce
various
types
such
optical,
electrochemical,
magnetic
biosensors,
along
with
their
respective
advantages
limitations.
Moreover,
summarizes
latest
advancements,
including
fabrication
techniques,
signal-amplification
strategies,
integration
microfluidics
nanotechnology.
Additionally,
challenges
future
perspectives
field
detection
are
discussed.
Understanding
these
can
greatly
contribute
improvements
diagnostics,
thereby
facilitating
early
personalized
treatments.
ACS Pharmacology & Translational Science,
Год журнала:
2024,
Номер
7(3), С. 586 - 613
Опубликована: Фев. 14, 2024
Cancer
is
one
of
the
leading
causes
death
worldwide.
Early
cancer
detection
critical
because
it
can
significantly
improve
treatment
outcomes,
thus
saving
lives,
reducing
suffering,
and
lessening
psychological
economic
burdens.
biomarkers
provide
varied
information
about
cancer,
from
early
malignancy
to
decisions
on
subsequent
monitoring.
A
large
variety
molecular,
histologic,
radiographic,
or
physiological
entities
features
are
among
common
types
biomarkers.
Sizeable
recent
methodological
progress
insights
have
promoted
significant
developments
in
field
Here
we
an
overview
advances
knowledge
related
biomolecules
cellular
used
for
detection.
We
examine
data
CAS
Content
Collection,
largest
human-curated
collection
published
scientific
information,
as
well
biomarker
datasets
at
Excelra,
analyze
publication
landscape
research.
also
discuss
evolution
key
concepts
development
pipelines,
with
a
particular
focus
pancreatic
liver
cancers,
which
known
be
remarkably
difficult
detect
particularly
high
morbidity
mortality.
The
objective
paper
broad
evolving
current
outline
challenges
evaluate
growth
opportunities,
order
further
efforts
solving
problems
that
remain.
merit
this
review
stems
extensive,
wide-ranging
coverage
most
up-to-date
allowing
unique,
unmatched
breadth
analysis
in-depth
insights.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(5), С. 2649 - 2649
Опубликована: Фев. 24, 2024
Gastric
cancer
(GC)
is
a
heterogeneous
disease,
often
diagnosed
at
advanced
stages,
with
5-year
survival
rate
of
approximately
20%.
Despite
notable
technological
advancements
in
research
over
the
past
decades,
their
impact
on
GC
management
and
outcomes
has
been
limited.
Numerous
molecular
alterations
have
identified
GC,
leading
to
various
classifications,
such
as
those
developed
by
The
Cancer
Genome
Atlas
(TCGA)
Asian
Research
Group
(ACRG).
Other
authors
proposed
alternative
perspectives,
including
immune,
proteomic,
or
epigenetic-based
classifications.
However,
stratification
not
yet
transitioned
into
clinical
practice
for
little
attention
paid
In
this
review,
we
explore
diverse
classifications
from
practical
point
view,
emphasizing
relationships
clinicopathological
factors,
prognosis,
therapeutic
approaches.
We
focused
beyond
TCGA
ACRG,
which
less
extensively
reviewed
previously.
Additionally,
discuss
challenges
that
must
be
overcome
ensure
patient
treatment
prognosis.
This
review
aims
serve
framework
understand
landscape
facilitate
development
consensus
categories,
guide
design
innovative
studies
field.
Critical Reviews in Clinical Laboratory Sciences,
Год журнала:
2024,
Номер
61(6), С. 473 - 495
Опубликована: Март 7, 2024
Nucleic
acids,
like
DNA
and
RNA,
serve
as
versatile
recognition
elements
in
electrochemical
biosensors,
demonstrating
notable
efficacy
detecting
various
cancer
biomarkers
with
high
sensitivity
selectivity.
These
biosensors
offer
advantages
such
cost-effectiveness,
rapid
response,
ease
of
operation,
minimal
sample
preparation.
This
review
provides
a
comprehensive
overview
recent
developments
nucleic
acid-based
for
diagnosis,
comparing
them
antibody-based
counterparts.
Specific
examples
targeting
key
biomarkers,
including
prostate-specific
antigen,
microRNA-21,
carcinoembryonic
are
highlighted.
The
discussion
delves
into
challenges
limitations,
encompassing
stability,
reproducibility,
interference,
standardization
issues.
suggests
future
research
directions,
exploring
new
acid
elements,
innovative
transducer
materials
designs,
novel
signal
amplification
strategies,
integration
microfluidic
devices
or
portable
instruments.
Evaluating
these
clinical
settings
using
actual
samples
from
patients
healthy
donors
is
emphasized.
sensors
sensitive
specific
at
non-communicable
communicable
disease
biomarkers.
RNA's
self-assembly,
programmability,
catalytic
activity,
dynamic
behavior
enable
adaptable
sensing
platforms.
They
can
increase
biosensor
biocompatibility,
transduction,
nanomaterials.
In
conclusion,
acids-based
hold
significant
potential
to
enhance
detection
treatment
through
early
accurate
diagnosis.
ACS Measurement Science Au,
Год журнала:
2024,
Номер
4(4), С. 315 - 337
Опубликована: Апрель 15, 2024
Recent
advancements
in
mass
spectrometry
(MS)
have
revolutionized
quantitative
proteomics,
with
multiplex
isotope
labeling
emerging
as
a
key
strategy
for
enhancing
accuracy,
precision,
and
throughput.
This
tutorial
review
offers
comprehensive
overview
of
techniques,
including
precursor-based,
defect-based,
reporter
ion-based,
hybrid
methods.
It
details
their
fundamental
principles,
advantages,
inherent
limitations
along
strategies
to
mitigate
the
limitation
ratio-distortion.
will
also
cover
applications
latest
progress
these
techniques
across
various
domains,
cancer
biomarker
discovery,
neuroproteomics,
post-translational
modification
analysis,
cross-linking
MS,
single-cell
proteomics.
Review
aims
provide
guidance
researchers
on
selecting
appropriate
methods
specific
goals
while
highlighting
potential
future
directions
this
rapidly
evolving
field.
Bioelectromagnetics,
Год журнала:
2025,
Номер
46(1)
Опубликована: Янв. 1, 2025
ABSTRACT
Cancer
remains
a
formidable
global
health
challenge,
necessitating
the
development
of
innovative
diagnostic
techniques
capable
early
detection
and
differentiation
tumor/cancerous
cells
from
their
healthy
counterparts.
This
review
focuses
on
confluence
advanced
computational
algorithms
with
noninvasive,
label‐free
impedance‐based
biophysical
methodologies—techniques
that
assess
biological
processes
directly
without
need
for
external
markers
or
dyes.
elucidates
diverse
array
state‐of‐the‐art
technologies,
illuminating
distinct
electrical
signatures
inherent
to
cancer
vs
tissues.
Additionally,
study
probes
transformative
potential
these
modalities
in
recalibrating
personalized
treatment
paradigms.
These
offer
real‐time
insights
into
tumor
dynamics,
paving
way
precision‐guided
therapeutic
interventions.
By
emphasizing
quest
continuous
vivo
monitoring,
herald
pivotal
advancement
overarching
endeavor
combat
globally.
Cancer Treatment and Research Communications,
Год журнала:
2025,
Номер
unknown, С. 100872 - 100872
Опубликована: Янв. 1, 2025
Colorectal
cancer
(CRC),
the
third
most
commonly
diagnosed
and
second
lethal
worldwide,
necessitates
efficient
early
detection
strategies
to
improve
patient
outcomes.
This
review
evaluates
promise
of
novel
blood-based
biomarkers
for
CRC.
A
systematic
review,
registered
with
PROSPERO
(CRD42024513770)
adhering
PRISMA
guidelines,
was
conducted
across
multiple
databases
from
January
1st,
2020
December
31st,
2022.
The
comprehensive
search
strategy
centered
on
sensitivity,
specificity,
AUC-ROC
types
molecular
blood
biomarkers.
Of
total
142
included
articles,
59
were
protein,
58
RNA,
21
DNA.
investigation
into
DNA
revealed
that
cfDNA
ctDNA
carry
significant
potential
CRC
diagnosis.
For
instance,
methylation
patterns
in
genes
such
as
MYO1-G
NDRG4
exhibited
high
diagnostic
accuracies
AUCs
reaching
up
0.996.
RNA
like
miRNAs
circRNAs
also
showed
promising
results,
circ_0011536
achieving
0.982.
Protein
biomarkers,
contrasted
established
markers,
unveiled
notable
candidates
Irisin
ANXA2,
surpassing
0.96.
highlights
several
individual
markers
panels
upon
existing
screening
tests.
Despite
shown
by
challenges
persist,
including
small
sample
sizes,
selection
biases,
a
lack
cost-effectiveness
analysis.
Future
research
should
focus
large-scale,
multicenter,
prospective
studies
diverse
populations.
findings
advocate
an
integrated
biomarker
approach,
potentially
revolutionizing
aligning
it
clinical
realities
through
rigorous
validation.
